bioAffinity Technologies, Inc. develops and commercializes noninvasive diagnostics for lung cancer and other lung diseases. The company’s first product, CyPath® Lung, is a sputum-based Laboratory Developed Test marketed by Precision Pathology Laboratory Services, a bioAffinity subsidiary, and uses flow cytometry with automated AI-informed analysis to identify cell populations associated with lung malignancy.
Recurring company news centers on CyPath® Lung commercialization, physician adoption, clinical case studies, pulmonary nodule management, lung cancer risk assessment, and post-treatment surveillance. Updates also cover financial results, laboratory-services focus, medical conference and physician-education activity, and research extending the company’s flow cytometry+AI platform toward asthma and COPD diagnostics.
bioAffinity Technologies, Inc. announced the pricing of its initial public offering (IPO) at $6.125 per unit, raising approximately $7,855,925 before expenses. The offering includes 1,282,600 units, each consisting of one share of common stock and two warrants for future stock purchase. The IPO is set to trade on the Nasdaq under symbols BIAF and BIAFW starting September 1, 2022. Proceeds will support the commercialization of the CyPath® Lung diagnostic test, which demonstrated 92% sensitivity and 87% specificity.